journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/28438510/disparities-in-the-management-of-patients-with-stage-i-small-cell-lung-carcinoma-sclc-a-surveillance-epidemiology-and-end-results-seer-analysis
#1
Zaheer Ahmed, Lara Kujtan, Kevin F Kennedy, John R Davis, Janakiraman Subramanian
INTRODUCTION: Patients with stage I small cell lung carcinoma (SCLC) are candidates for surgery; however, not much is known regarding the utilization of surgical resection in the management of stage I SCLC and the factors that determine the patient's ability to receive surgery. METHODS: The Surveillance, Epidemiology and End Results database was used to identify patients with stage I SCLC from 2007 to 2013. Continuous variables were compared with 1-way analysis of variance, and categorical variables were compared with χ(2) testing...
March 30, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28416261/feasibility-study-of-personalized-peptide-vaccination-for-advanced-small-cell-lung-cancer
#2
Shinjiro Sakamoto, Teppei Yamada, Yasuhiro Terazaki, Koichi Yoshiyama, Shunichi Sugawara, Shinzo Takamori, Satoko Matsueda, Shigeki Shichijo, Akira Yamada, Masanori Noguchi, Kyogo Itoh, Noboru Hattori, Nobuoki Kohno, Tetsuro Sasada
INTRODUCTION: The prognosis of patients with small cell lung cancer (SCLC) remains very poor. Therefore, the development of new therapeutic approaches, including immunotherapies, is desirable. PATIENTS AND METHODS: We conducted a phase II study of personalized peptide vaccination (PPV), in which a maximum of 4 human leukocyte antigen-matched peptides were selected from 31 pooled peptides according to the pre-existing peptide-specific IgG responses before vaccination...
March 24, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28416124/assessment-of-the-external-validity-of-the-national-comprehensive-cancer-network-and-european-society-for-medical-oncology-guidelines-for-non-small-cell-lung-cancer-in-a-population-of-patients-aged-80-years-and-older
#3
REVIEW
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann
Non-small-cell lung cancer (NSCLC) is a disease of the elderly, who are under-represented in clinical trials. This challenges the external validity of the evidence base for its management and of current guidelines, that we evaluated in a population of older patients. We retrieved randomized clinical trials (RCTs) supporting the guidelines and identified 18 relevant topics. We matched a cohort of NSCLC patients aged older than 80 years from the Moffitt Cancer Center database with the studies' eligibility criteria to check their qualification for at least 2 studies...
March 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28408183/outcomes-of-stereotactic-body-radiotherapy-for-t1-t2n0-small-cell-carcinoma-according-to-addition-of-chemotherapy-and-prophylactic-cranial-irradiation-a-multicenter-analysis
#4
Vivek Verma, Charles B Simone, Pamela K Allen, Steven H Lin
BACKGROUND: Although T1-T2N0 non-small cell lung cancer can be managed with stereotactic body radiotherapy (SBRT) alone, this management has often been extrapolated to T1-T2N0 small cell lung cancer (SCLC). This secondary analysis of a multi-institutional cohort study investigated whether the addition of chemotherapy and prophylactic cranial irradiation (PCI) improved the outcomes for these patients. MATERIALS AND METHODS: All cases of histologically confirmed T1-T2N0M0 SCLC were obtained from 24 institutions' prospectively collected SBRT databases...
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28385373/computed-tomography-features-of-lung-adenocarcinomas-with-programmed-death-ligand-1-expression
#5
Gouji Toyokawa, Kazuki Takada, Tatsuro Okamoto, Mototsugu Shimokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Masakazu Katsura, Fumihiro Shoji, Yoshinao Oda, Yoshihiko Maehara
INTRODUCTION: The development of immune checkpoint inhibitors against programmed death 1 has paved the way for a new era of treatment of lung cancer. Programmed death-ligand 1 (PD-L1) is expected to predict the response of immune checkpoint inhibitors in lung cancer. Predicting PD-L1 expression using a noninvasive method before immunotherapy would, therefore, help identify patients for whom immunotherapy can be successful. PATIENTS AND METHODS: A total of 394 patients with resected lung adenocarcinoma who had undergone preoperative thin-section computed tomography (CT) were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and CT characteristics, including convergence, surrounding ground glass opacity (GGO), air bronchogram, notching, pleural indentation, spiculation, and cavitation...
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28385372/enrollment-of-elderly-patients-with-locally-advanced-non-small-cell-lung-cancer-in-multi-institutional-trials-of-proton-beam-radiation-therapy
#6
Vivek Verma, Jean-Claude M Rwigema, Sebastian Adeberg, Charles B Simone
No abstract text is available yet for this article.
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28373068/stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer-in-patients-80-years-and-older-a-multi-center-analysis
#7
Richard J Cassidy, Pretesh R Patel, Xinyan Zhang, Robert H Press, Jeffrey M Switchenko, Rathi N Pillai, Taofeek K Owonikoko, Suresh S Ramalingam, Felix G Fernandez, Seth D Force, Walter J Curran, Kristin A Higgins
BACKGROUND: Stereotactic body radiotherapy (SBRT) is the standard of care for medically inoperable early-stage non-small-cell lung cancer. Despite the limited number of octogenarians and nonagenarians on trials of SBRT, its use is increasingly being offered in these patients, given the aging cancer population, medical fragility, or patient preference. Our purpose was to investigate the efficacy, safety, and survival of patients ≥ 80 years old treated with definitive lung SBRT. METHODS: Patients who underwent SBRT were reviewed from 2009 to 2015 at 4 academic centers...
March 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28377206/ablative-therapy-for-oligometastatic-non-small-cell-lung-cancer
#8
REVIEW
Oscar Juan, Sanjay Popat
The oligometastatic state represents a distinct entity among those with metastatic disease and consists of patients with metastases limited in number and location, representing an intermediate state between locally confined and widely metastatic cancer. Although similar, "oligorecurrence" (limited number of metachronous metastases under conditions of a controlled primary lesion) and "oligoprogressive" (disease progression at a limited number of sites with disease controlled at other disease sites) states are distinct entities...
March 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28377205/molecular-testing-turnaround-time-for-non-small-cell-lung-cancer-in-routine-clinical%C3%A2-practice-confirms-feasibility-of-cap-iaslc-amp-guideline-recommendations-a-single-center-analysis
#9
Marcello DiStasio, Yigu Chen, Deepa Rangachari, Daniel B Costa, Yael K Heher, Paul A VanderLaan
INTRODUCTION: Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced-stage non-small cell lung cancer. Recent guideline recommendations by the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT) target of 10 working days for results to be available to the treating oncologist and ≤ 3 days for specimens to arrive at a commercial testing laboratory if testing is not performed in-house...
March 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28373069/interstitial-lung-disease-associated-with-crizotinib-in-patients-with-advanced-non-small-cell-lung-cancer-independent-review-of-four-profile-trials
#10
Ken Y Yoneda, Judith R Scranton, Michael A Cadogan, Vanessa Tassell, Sashi Nadanaciva, Keith D Wilner, Nicholas S Stollenwerk
INTRODUCTION: Interstitial lung disease (ILD) is a rare, but potentially serious, side effect associated with crizotinib, a tyrosine kinase inhibitor for anaplastic lymphoma kinase-positive (ALK(+)) advanced non-small cell lung cancer. Our objective was to determine the incidence and nature of ILD associated with crizotinib in 4 PROFILE trials (ClinicalTrials.gov identifiers, NCT00585195, NCT00932451, NCT00932893, and NCT01154140). MATERIALS AND METHODS: Grade ≥ 3 respiratory adverse events (AEs) and serious AEs (SAEs) and any grade AEs/SAEs reported as pneumonitis, ILD, or radiation pneumonitis in trials PROFILE 1001, PROFILE 1005, PROFILE 1007, and PROFILE 1014 were evaluated by an expert independent review committee that included a pulmonologist, medical oncologist, and radiologist...
March 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28412094/emotional-problems-quality-of-life-and-symptom-burden-in-patients-with-lung-cancer
#11
Eleshia J Morrison, Paul J Novotny, Jeff A Sloan, Ping Yang, Christi A Patten, Kathryn J Ruddy, Matthew M Clark
OBJECTIVES: Lung cancer is associated with a greater symptom burden than other cancers, yet little is known about the prevalence of emotional problems and how emotional problems may be related to the physical symptom burden and quality of life in newly diagnosed patients with lung cancer. This study aimed to identify the patient and disease characteristics of patients with lung cancer experiencing emotional problems and to examine how emotional problems relate to quality of life and symptom burden...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28412093/non-small-cell-lung-cancer-as-a-second-primary-among-patients-with-previous-malignancy-who-is-at-risk
#12
Geena X Wu, Rebecca A Nelson, Jae Y Kim, Dan J Raz
BACKGROUND: Patients with previous malignancies could be at increased risk of non-small cell lung cancer (NSCLC). However, the extent of the risk is unknown for many cancer types; thus, it is unclear who might benefit from screening. MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results data set from 1992 to 2012 was used to identify patients with previous malignancies who received a diagnosis of NSCLC ≥ 6 months after their initial cancer diagnosis...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28365238/an-open-label-randomized-controlled-phase-ii-study-of-paclitaxel-carboplatin-chemotherapy-with-necitumumab-versus-paclitaxel-carboplatin-alone-in-first-line-treatment-of-patients-with-stage-iv-squamous-non-small-cell-lung-cancer
#13
David R Spigel, Alexander Luft, Henrik Depenbrock, Rodryg Ramlau, Mazen Khalil, Joo-Hang Kim, Carlos Mayo, Grace Yi Chao, Coleman Obasaju, Ronald Natale
BACKGROUND: The combination of necitumumab with gemcitabine-cisplatin significantly improved overall survival (OS) in patients with stage IV squamous non-small-cell lung cancer (NSCLC), in the phase III SQUamous NSCLC treatment with the Inhibitor of EGF REceptor (SQUIRE) trial. Paclitaxel-carboplatin was selected as an alternative standard of care in the current phase II study. PATIENTS AND METHODS: Patients were randomized (stratified according to Eastern Cooperative Oncology Group performance status and sex) 2:1 to ≤ six 3-week cycles (Q3W) of paclitaxel and carboplatin with or without necitumumab...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28342728/comparative-analysis-for-diagnostic-yield-of-small-cell-lung-cancer-by-cytology-and%C3%A2-histology-during-the-same-bronchoscopic%C3%A2-procedure
#14
Wei-Nan Li, Di-Fei Wang, Ya-Bin Zhao, Xue-Shan Qiu, En-Hua Wang, Guang-Ping Wu
BACKGROUND: Biopsy, brushing, and transbronchial needle aspiration (TBNA) are the most common methods used for the diagnosis of small cell lung cancer during the same diagnostic bronchoscopic procedure. However, it is not clear which method provides better results. PATIENTS AND METHODS: A retrospective analysis was performed of 140 patients who had undergone video bronchoscopy for diagnostic purposes. Bronchial brushings were obtained from all subjects. Biopsy specimens were also obtained from all subjects, except for 6 cases that could not be sampled; the TBNA method was used for some special lesions...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28320638/prognostic-value-of-geriatric-8-and-identification-of-seniors-at-risk-for-hospitalized-patients-screening-tools-for-patients-with-lung-cancer
#15
Karlijn J G Schulkes, Esteban T D Souwer, Leontine J R van Elden, Henk Codrington, Simone van der Sar-van der Brugge, Jan-Willem J Lammers, Johanneke E A Portielje, Frederiek van den Bos, Marije E Hamaker
BACKGROUND: Because of the time-consuming aspect of geriatric assessments, cancer specialists are seeking shorter screening tools to distinguish fit and frail patients. We analyzed the predictive value of the Geriatric 8 (G8) and Identification of Seniors at Risk for Hospitalized Patients (ISAR-HP) in elderly patients with lung cancer. PATIENTS AND METHODS: From January 2014 to April 2016, the data from patients with lung cancer aged > 70 years at 2 teaching hospitals in the Netherlands were included in a database...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28318951/a-comprehensive-analysis-of-programmed-cell-death-ligand-1-expression-with-the-clone-sp142-antibody-in-non-small-cell-lung-cancer%C3%A2-patients
#16
Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Mototsugu Shimokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with anti-PD-1 therapy currently the standard treatment for non-small-cell lung cancer (NSCLC) patients after the failure of first-line chemotherapy treatment. The recent phase II POPLAR and phase III OAK studies showed that atezolizumab, a representative PD-L1 inhibitor, exhibited a survival benefit compared with standard therapy in patients with NSCLC...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28344046/long-term-outcomes-of-induction-carboplatin-and-gemcitabine-followed-by-concurrent-radiotherapy-with-low-dose-paclitaxel-and-gemcitabine-for-stage-iii-non-small-cell-lung%C3%A2-cancer
#17
Catherine Guilbault, Aurelie Garant, Sergio Faria, Scott Owen, Linda Ofiara, Marie Duclos, Vera Hirsh, Neil Kopek
BACKGROUND: Standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC) is concurrent chemo-radiation (CRT). A regimen of induction carboplatin and gemcitabine followed by CRT was developed at the McGill University Health Centre to prevent delays in treatment initiation. We report the long-term outcomes with this regimen based on a pooled analysis of both protocol patients from a phase II study and nonprotocol patients. METHODS AND MATERIALS: Outcomes and toxicity data were retrieved for 142 patients with stage III NSCLC: 43 patients treated on protocol between January 2003 and November 2004, and 101 patients treated off-protocol between December 2004 and August 2013...
March 1, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28341106/the-apple-trial-feasibility-and-activity-of-azd9291-osimertinib-treatment-on-positive-plasma-t790m-in-egfr-mutant-nsclc-patients-eortc-1613
#18
Jordi Remon, Jessica Menis, Baktiar Hasan, Aleksandra Peric, Eleonora De Maio, Silvia Novello, Martin Reck, Thierry Berghmans, Bartosz Wasag, Benjamin Besse, Rafal Dziadziuszko
The AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients (APPLE) trial is a randomized, open-label, multicenter, 3-arm, phase II study in advanced, epidermal growth factor receptor (EGFR)-mutant and EGFR tyrosine kinase inhibitor (TKI)-naive non-small-cell lung cancer (NSCLC) patients, to evaluate the best strategy for sequencing gefitinib and osimertinib treatment. Advanced EGFR-mutant NSCLC patients, with World Health Organization performance status 0-2 who are EGFR TKI treatment-naive and eligible to receive first-line treatment with EGFR TKI will be randomized to: In all arms, a plasmatic ctDNA T790M test will be performed by a central laboratory at the Medical University of Gdansk (Poland) but will be applied as a predictive marker for making treatment decisions only in arm B...
March 1, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28302437/definitive-radiotherapy-for-local-recurrence-of-nsclc-after-surgery
#19
Abraham J Wu, Elizabeth Garay, Amanda Foster, Meier Hsu, Zhigang Zhang, Jamie E Chaft, James Huang, Kenneth E Rosenzweig, Andreas Rimner
INTRODUCTION: Locoregional recurrence after resection of non-small-cell lung cancer (NSCLC) is common. We examined outcomes after definitive radiotherapy (RT) to identify prognostic factors for survival and further recurrence. PATIENTS AND METHODS: We reviewed 152 patients who received RT for locoregional recurrent (LR)-NSCLC, and analyzed subsequent overall survival (OS), locoregional failure (LRF), distant metastasis (DM), and any disease progression (LRF and DM)...
February 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28416123/immune-checkpoint-inhibitors-for-patients-with-advanced-non-small-cell-lung-cancer-a%C3%A2-systematic-review
#20
REVIEW
Peter M Ellis, Emily T Vella, Yee C Ung
Second-line treatment options are limited for patients with advanced non-small-cell lung cancer (NSCLC). Standard therapy includes the cytotoxic agents docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiologic response rates and have been well tolerated. The objective of this systematic review was to investigate the efficacy of immune checkpoint inhibitors compared with other chemotherapies in patients with advanced NSCLC...
February 16, 2017: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"